Biologic dose tailoring in Crohn disease

E-ISSN： 1445-5994|45|2|170-177

ISSN： 1444-0903

Source： INTERNAL MEDICINE JOURNAL, Vol.45, Iss.2, 2015-02, pp. : 170-177

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Biologic Drugs in Crohn's Disease and Ulcerative Colitis: Safety Profile

Current Drug Safety, Vol. 11, Iss. 1, 2016-03 ,pp. : 55-61

Bentham Science Publishers

Access to resources Recommend Favorite

Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease – a SONIC post hoc analysis

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 8, 2015-04 ,pp. : 734-746

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of infliximab with adalimumab in 827 biologic‐naïve patients with Crohn's disease: a population‐based Danish cohort study

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 5, 2018-03 ,pp. : 596-604

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: effectiveness of split‐dose certolizumab pegol for Crohn's disease

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 38, Iss. 11-12, 2013-12 ,pp. : 1412-1412

John Wiley & Sons Inc

Access to resources Recommend Favorite

Biologic Markers in Alzheimer's Disease

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 33, Iss. 10, 1985-10 ,pp. : 715-726

John Wiley & Sons Inc

Access to resources Recommend Favorite